A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinoma
Authors:
Open Access
- 22 August 2025
- journal article
- Published by Elsevier in JHEP Reports
- Vol. 7 (11) , 101557
Abstract
No abstract availableKeywords
Funding Information
- Taishan Scholar Foundation of Shandong Province (tstp20221158)
- Taishan Scholar Foundation of Shandong Province (tsqnz20221164)
- National Natural Science Foundation of China (82203000)
- National Natural Science Foundation of China (81874178)
- National Natural Science Foundation of China (82073200)
- Natural Science Foundation of Shandong Province (ZR2022QH300)
- Natural Science Foundation of Shandong Province (ZR2021ZD26)
This publication has 39 references indexed in Scilit:
- Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selectionComputational and Structural Biotechnology Journal, 2024
- Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon CancerJAMA Surgery, 2024
- Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2024
- EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinomaJournal of Hepatology, 2023
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantationHepatology International, 2023
- Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancerCancer Immunology, Immunotherapy, 2019
- Pseudoprogression and hyperprogression after checkpoint blockadeInternational Immunopharmacology, 2018
- Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysisJournal of Surgical Oncology, 2017
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupEuropean Journal of Cancer, 2016